Lupin is currently trading at Rs. 1279.50, up by 23.95 points or 1.91% from its previous closing of Rs. 1255.55 on the BSE.
The scrip opened at Rs. 1261.85 and has touched a high and low of Rs. 1283.60 and Rs. 1258.70 respectively. So far 11304 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1319.90 on 04-Dec-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1287.35 and Rs. 1200.35 respectively. The current market cap of the company is Rs. 58054.14 crore.
The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.
Lupin’s consumer healthcare business -- LupinLife has launched Softovac Liquifibre, a 100% Ayurvedic liquid laxative. With this, the company enters the Indian liquid laxative market with this innovative product that is a formulation of Isabgol fibre in liquid form and natural actives such as Sonamukhi, Harad, Mulethi, Saunf, Amaltas and Gulab Dal.
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients. The product has been proven safe and clinically efficacious versus benchmark liquid laxative products.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1340.80 |
Cipla | 1476.45 |
Lupin | 2160.20 |
Zydus Lifesciences | 972.95 |
View more.. |